Cervical cancer prevention in the era of prophylactic vaccines

A preview for gynecologic oncologists

Yvonne Collins, Mark H. Einstein, Bobbie S. Gostout, Thomas J. Herzog, L. Stuart Massad, Janet S. Rader, Jason Wright

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Objective: The recent approval of a vaccine to prevent HPV infection is an important advance in cervical cancer prevention. This article is intended to provide gynecologic oncologists with a comprehensive background in modern cervical cancer prevention strategies. Methods: We describe and contrast the quadrivalent and bivalent vaccines. More established cervical cancer prevention strategies are reviewed, with comments on the impact of HPV vaccination. Clinical guidance is provided for use of the approved quadrivalent vaccine. Safety and side effects of both vaccines are reviewed and future questions and challenges are explored. Results: It is vitally important that both vaccinated and unvaccinated women continue to fully engage in cervical cancer prevention, including cervical cancer screening, follow-up of abnormal screens, and treatment of premalignant lesions. A quadrivalent virus-like particle vaccine has now been approved for use in girls and women ages 9 to 26. A bivalent vaccine may be available soon. Vaccine efficacy in clinical trials has been outstanding, with 100% protection against HPV-type-specific cervical intraepithelial neoplasia (CIN) II and III. Conclusions: Comprehensive cervical cancer protection now includes prophylactic vaccination for girls and young women in addition to screening and treatment of premalignant changes. Gynecologic oncologists will continue to play an important role in promoting optimal prevention practices.

Original languageEnglish (US)
Pages (from-to)552-562
Number of pages11
JournalGynecologic Oncology
Volume102
Issue number3
DOIs
StatePublished - Sep 2006

Fingerprint

Uterine Cervical Neoplasms
Vaccines
Vaccination
Virus-Like Particle Vaccines
Cervical Intraepithelial Neoplasia
Early Detection of Cancer
Oncologists
Clinical Trials
Safety
Therapeutics
Infection

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Collins, Y., Einstein, M. H., Gostout, B. S., Herzog, T. J., Massad, L. S., Rader, J. S., & Wright, J. (2006). Cervical cancer prevention in the era of prophylactic vaccines: A preview for gynecologic oncologists. Gynecologic Oncology, 102(3), 552-562. https://doi.org/10.1016/j.ygyno.2006.07.022

Cervical cancer prevention in the era of prophylactic vaccines : A preview for gynecologic oncologists. / Collins, Yvonne; Einstein, Mark H.; Gostout, Bobbie S.; Herzog, Thomas J.; Massad, L. Stuart; Rader, Janet S.; Wright, Jason.

In: Gynecologic Oncology, Vol. 102, No. 3, 09.2006, p. 552-562.

Research output: Contribution to journalArticle

Collins, Y, Einstein, MH, Gostout, BS, Herzog, TJ, Massad, LS, Rader, JS & Wright, J 2006, 'Cervical cancer prevention in the era of prophylactic vaccines: A preview for gynecologic oncologists', Gynecologic Oncology, vol. 102, no. 3, pp. 552-562. https://doi.org/10.1016/j.ygyno.2006.07.022
Collins, Yvonne ; Einstein, Mark H. ; Gostout, Bobbie S. ; Herzog, Thomas J. ; Massad, L. Stuart ; Rader, Janet S. ; Wright, Jason. / Cervical cancer prevention in the era of prophylactic vaccines : A preview for gynecologic oncologists. In: Gynecologic Oncology. 2006 ; Vol. 102, No. 3. pp. 552-562.
@article{bf189151cf364b98a24641dfe4751c37,
title = "Cervical cancer prevention in the era of prophylactic vaccines: A preview for gynecologic oncologists",
abstract = "Objective: The recent approval of a vaccine to prevent HPV infection is an important advance in cervical cancer prevention. This article is intended to provide gynecologic oncologists with a comprehensive background in modern cervical cancer prevention strategies. Methods: We describe and contrast the quadrivalent and bivalent vaccines. More established cervical cancer prevention strategies are reviewed, with comments on the impact of HPV vaccination. Clinical guidance is provided for use of the approved quadrivalent vaccine. Safety and side effects of both vaccines are reviewed and future questions and challenges are explored. Results: It is vitally important that both vaccinated and unvaccinated women continue to fully engage in cervical cancer prevention, including cervical cancer screening, follow-up of abnormal screens, and treatment of premalignant lesions. A quadrivalent virus-like particle vaccine has now been approved for use in girls and women ages 9 to 26. A bivalent vaccine may be available soon. Vaccine efficacy in clinical trials has been outstanding, with 100{\%} protection against HPV-type-specific cervical intraepithelial neoplasia (CIN) II and III. Conclusions: Comprehensive cervical cancer protection now includes prophylactic vaccination for girls and young women in addition to screening and treatment of premalignant changes. Gynecologic oncologists will continue to play an important role in promoting optimal prevention practices.",
author = "Yvonne Collins and Einstein, {Mark H.} and Gostout, {Bobbie S.} and Herzog, {Thomas J.} and Massad, {L. Stuart} and Rader, {Janet S.} and Jason Wright",
year = "2006",
month = "9",
doi = "10.1016/j.ygyno.2006.07.022",
language = "English (US)",
volume = "102",
pages = "552--562",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Cervical cancer prevention in the era of prophylactic vaccines

T2 - A preview for gynecologic oncologists

AU - Collins, Yvonne

AU - Einstein, Mark H.

AU - Gostout, Bobbie S.

AU - Herzog, Thomas J.

AU - Massad, L. Stuart

AU - Rader, Janet S.

AU - Wright, Jason

PY - 2006/9

Y1 - 2006/9

N2 - Objective: The recent approval of a vaccine to prevent HPV infection is an important advance in cervical cancer prevention. This article is intended to provide gynecologic oncologists with a comprehensive background in modern cervical cancer prevention strategies. Methods: We describe and contrast the quadrivalent and bivalent vaccines. More established cervical cancer prevention strategies are reviewed, with comments on the impact of HPV vaccination. Clinical guidance is provided for use of the approved quadrivalent vaccine. Safety and side effects of both vaccines are reviewed and future questions and challenges are explored. Results: It is vitally important that both vaccinated and unvaccinated women continue to fully engage in cervical cancer prevention, including cervical cancer screening, follow-up of abnormal screens, and treatment of premalignant lesions. A quadrivalent virus-like particle vaccine has now been approved for use in girls and women ages 9 to 26. A bivalent vaccine may be available soon. Vaccine efficacy in clinical trials has been outstanding, with 100% protection against HPV-type-specific cervical intraepithelial neoplasia (CIN) II and III. Conclusions: Comprehensive cervical cancer protection now includes prophylactic vaccination for girls and young women in addition to screening and treatment of premalignant changes. Gynecologic oncologists will continue to play an important role in promoting optimal prevention practices.

AB - Objective: The recent approval of a vaccine to prevent HPV infection is an important advance in cervical cancer prevention. This article is intended to provide gynecologic oncologists with a comprehensive background in modern cervical cancer prevention strategies. Methods: We describe and contrast the quadrivalent and bivalent vaccines. More established cervical cancer prevention strategies are reviewed, with comments on the impact of HPV vaccination. Clinical guidance is provided for use of the approved quadrivalent vaccine. Safety and side effects of both vaccines are reviewed and future questions and challenges are explored. Results: It is vitally important that both vaccinated and unvaccinated women continue to fully engage in cervical cancer prevention, including cervical cancer screening, follow-up of abnormal screens, and treatment of premalignant lesions. A quadrivalent virus-like particle vaccine has now been approved for use in girls and women ages 9 to 26. A bivalent vaccine may be available soon. Vaccine efficacy in clinical trials has been outstanding, with 100% protection against HPV-type-specific cervical intraepithelial neoplasia (CIN) II and III. Conclusions: Comprehensive cervical cancer protection now includes prophylactic vaccination for girls and young women in addition to screening and treatment of premalignant changes. Gynecologic oncologists will continue to play an important role in promoting optimal prevention practices.

UR - http://www.scopus.com/inward/record.url?scp=33748493750&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748493750&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2006.07.022

DO - 10.1016/j.ygyno.2006.07.022

M3 - Article

VL - 102

SP - 552

EP - 562

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -